M. D’Arcangelo

1.5k total citations
31 papers, 360 citations indexed

About

M. D’Arcangelo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M. D’Arcangelo has authored 31 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 21 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in M. D’Arcangelo's work include Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (9 papers). M. D’Arcangelo is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Research Studies (9 papers). M. D’Arcangelo collaborates with scholars based in Italy, United States and Spain. M. D’Arcangelo's co-authors include Federico Cappuzzo, Fred R. Hirsch, Lorenza Landi, Armida D’Incecco, R. Di Marsico, Alfredo Falcone, C. Galli, Paola Orlandi, Luca Galli and Giacomo Allegrini and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

M. D’Arcangelo

29 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. D’Arcangelo Italy 12 200 196 119 79 41 31 360
Danmei Pang China 7 196 1.0× 151 0.8× 117 1.0× 113 1.4× 31 0.8× 17 357
Davide Bosso Italy 12 132 0.7× 167 0.9× 133 1.1× 70 0.9× 41 1.0× 18 366
Chester Kao United States 8 164 0.8× 160 0.8× 110 0.9× 108 1.4× 43 1.0× 19 330
Nishi Kothari United States 12 238 1.2× 155 0.8× 93 0.8× 74 0.9× 39 1.0× 29 372
Umair Majeed United States 5 149 0.7× 159 0.8× 95 0.8× 81 1.0× 19 0.5× 27 295
Erion Dobi France 14 217 1.1× 147 0.8× 74 0.6× 111 1.4× 14 0.3× 31 356
Bastianina Canu Italy 10 197 1.0× 103 0.5× 136 1.1× 84 1.1× 16 0.4× 15 346
Arpita Desai United States 10 165 0.8× 185 0.9× 229 1.9× 116 1.5× 31 0.8× 38 451
James D. Peyton United States 10 200 1.0× 145 0.7× 175 1.5× 53 0.7× 26 0.6× 27 363
Aurélie Swalduz France 11 182 0.9× 200 1.0× 126 1.1× 92 1.2× 28 0.7× 63 334

Countries citing papers authored by M. D’Arcangelo

Since Specialization
Citations

This map shows the geographic impact of M. D’Arcangelo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. D’Arcangelo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. D’Arcangelo more than expected).

Fields of papers citing papers by M. D’Arcangelo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. D’Arcangelo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. D’Arcangelo. The network helps show where M. D’Arcangelo may publish in the future.

Co-authorship network of co-authors of M. D’Arcangelo

This figure shows the co-authorship network connecting the top 25 collaborators of M. D’Arcangelo. A scholar is included among the top collaborators of M. D’Arcangelo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. D’Arcangelo. M. D’Arcangelo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Spicer, Jonathan, Nicolas Girard, Mariano Provencio, et al.. (2024). Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.. Journal of Clinical Oncology. 42(17_suppl). LBA8010–LBA8010. 25 indexed citations
3.
Hanley, Michael J., M. D’Arcangelo, Enriqueta Felip, et al.. (2022). A Phase 1 Drug‐Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK‐Positive or ROS1‐Positive Solid Tumors. The Journal of Clinical Pharmacology. 63(5). 583–592. 2 indexed citations
4.
Ahn, M-J., S-W. Kim, Enric Carcereny, et al.. (2022). LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin/pemetrexed (CP) in treatment-naïve (1L) non-small cell lung cancer (NSCLC): A phase Ib/II trial. Annals of Oncology. 33. S1423–S1423. 15 indexed citations
5.
Bravaccini, Sara, Giuseppe Bronte, Elisabetta Petracci, et al.. (2021). The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects. Frontiers in Cell and Developmental Biology. 9. 772216–772216. 5 indexed citations
6.
7.
Pezzuto, Aldo, Federico Cappuzzo, M. D’Arcangelo, et al.. (2020). Prognostic Value of p16 Protein in Patients With Surgically Treated Non-small Cell Lung Cancer; Relationship With Ki-67 and PD-L1. Anticancer Research. 40(2). 983–990. 17 indexed citations
8.
Landi, Lorenza, Marcello Tiseo, Lukas C. Heukamp, et al.. (2019). P1.14-03 Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial. Journal of Thoracic Oncology. 14(10). S553–S553. 1 indexed citations
9.
D’Arcangelo, M., Davide Tassinari, Filippo de Marinis, et al.. (2019). P2.01-15 Phase II Single Arm Study of CABozantinib in Non-Small Cell Lung Cancer Patients with MET Deregulation (CABinMET). Journal of Thoracic Oncology. 14(10). S644–S644. 9 indexed citations
10.
D’Incecco, Armida, Marianna Gallo, Antonella De Luca, et al.. (2017). Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC). Annals of Oncology. 28. vi62–vi62. 1 indexed citations
11.
Bennati, Chiara, M. D’Arcangelo, Gabriele Minuti, et al.. (2017). Integrating programmed cell death ligand 1 (PD-L1) and neutrophil to lymphocyte ratio (NLR) as predictive panel of response to nivolumab in non-small cell lung cancer (NSCLC). Annals of Oncology. 28. vi56–vi56. 1 indexed citations
12.
Kristeleit, Rebecca, T.R. Jeffry Evans, Sarah Slater, et al.. (2016). A Phase 1 study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 34(15_suppl). TPS2594–TPS2594. 1 indexed citations
13.
D’Arcangelo, M., Matilde Todaro, Jessica Salvini, et al.. (2015). Cancer Stem Cells Sensitivity Assay (STELLA) in Patients with Advanced Lung and Colorectal Cancer: A Feasibility Study. PLoS ONE. 10(5). e0125037–e0125037. 13 indexed citations
14.
Hirsch, Fred R. & M. D’Arcangelo. (2014). Clinical and comparative utility of afatinib in non-small cell lung cancer. Biologics. 8. 183–183. 26 indexed citations
15.
D’Arcangelo, M., Armida D’Incecco, & Federico Cappuzzo. (2013). Rare Mutations in Non-Small-Cell Lung Cancer. Future Oncology. 9(5). 699–711. 19 indexed citations
16.
D’Arcangelo, M. & Federico Cappuzzo. (2013). Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer. Biologics. 7. 61–61. 33 indexed citations
17.
Mok, Tony, M. D’Arcangelo, & Raffaele Califano. (2012). Clinical Outcomes with Erlotinib in Patients with Epidermal Growth Factor Receptor Mutation. Drugs. 72. 3–10. 5 indexed citations
18.
D’Arcangelo, M. & Federico Cappuzzo. (2012). K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value. PubMed. 2012. 1–8. 22 indexed citations
19.
Landi, Lorenza, Domenico Galetta, Chiara Bennati, et al.. (2012). Efficacy of the Irreversible EGFR-HER2 Dual Inhibitor Afatinib in Pretreated Lung Adenocarcinoma. Annals of Oncology. 23. ix423–ix423. 1 indexed citations
20.
Maio, Ermelinda De, Carmelo Tibaldi, Armida D’Incecco, et al.. (2010). Consequences of targeted treatments for second-line therapy. Annals of Oncology. 21. vii234–vii240. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Danmei Pang Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Chester Kao Breakdown of academic impact, for papers by Nishi Kothari Breakdown of academic impact, for papers by Umair Majeed Breakdown of academic impact, for papers by Erion Dobi Breakdown of academic impact, for papers by Bastianina Canu Breakdown of academic impact, for papers by Arpita Desai Breakdown of academic impact, for papers by James D. Peyton Breakdown of academic impact, for papers by Aurélie Swalduz
Rankless by CCL
2026